Taysha Gene Therapies (NASDAQ: TSHA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.070 | -1.310 | -0.2400 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Taysha Gene Therapies (NASDAQ: TSHA) through any online brokerage.
Other companies in Taysha Gene Therapies’s space includes: Graphite Bio (NASDAQ:GRPH), Jounce Therapeutics (NASDAQ:JNCE), Humanigen (NASDAQ:HGEN), Sesen Bio (NASDAQ:SESN) and Olema Pharmaceuticals (NASDAQ:OLMA).
The latest price target for Taysha Gene Therapies (NASDAQ: TSHA) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 16.00 expecting TSHA to rise to within 12 months (a possible 304.04% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Taysha Gene Therapies (NASDAQ: TSHA) is $3.96 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Taysha Gene Therapies.
Taysha Gene Therapies’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Taysha Gene Therapies.
Taysha Gene Therapies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.